Chris Gordon

Global Head of Private Equity, Bain Capital · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

investorexecutivebaincapital.com/people/chris-gordon ↗

Chris Gordon joined Bain Capital in 1997, where he oversees the firm's global private equity operations and healthcare investment vertical, and helped launch its life sciences practice in 2016. He has led major healthcare investments, serving on the boards of HCA Healthcare, IQVIA, Acadia Healthcare, Waystar, and Surgery Partners.

25statements → 13claims → 12claims resolved → 92%fully supported → 3.92/5average certainty → 1.28/5average debate potential → ≈4.5/5argument clarity, estimated →

11 supported 0 partly supported 1 contradicted 1 not checkable as stated how the 13 claims stand · each chip opens the sources

13 assertions · 8 insights · 4 disclosures · every statement was checked. The predictions and assertions are the 13 claims: statements the public record can support or contradict. 12 are resolved, and 1 names no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Chris argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported

2006 HCA Buyout Had a $33 Billion Enterprise Value

“Nobody would have really believed, and frankly, we weren't even sure in that 2005, six timeframe, could you really do a deal as big as HCA, which was a thirty-three billion dollar enterprise value transaction.”

Chris Gordon Aug 28, 2023 ▶ 9:40 Classic Deal: HCA – Chris Gordon, Bain Capital (EP.335)

Their most notable contradicted claim

Assertion Contradicted

Gordon: HCA's IPO Raised Mainly Secondary Capital, Not Debt Paydown

“The IPO is actually mainly Secondary capital, because we had done a good job of growing into our capital structure and already going down the path of spreading it over time.”

Chris Gordon Aug 28, 2023 ▶ 41:46 Classic Deal: HCA – Chris Gordon, Bain Capital (EP.335)

Expressed certainty vs assessment result

none yet certainty 1

none yet certainty 2

100% certainty 3

90% certainty 4

100% certainty 5

weighted support: a fully supported claim counts one, a partly supported claim counts half. Each filled bar is clickable and opens exactly those claims; "none yet" means nothing said at that certainty level has resolved yet

How they sound: not measured why? →

We measure speaking style by listening to the audio itself, and a fair number needs at least 2,000 words from one person on tape we have measured. There is too little of Chris Gordon on measured tape to publish a rate. This says nothing about how they speak.

What they said25 Episodes1

Everything Chris Gordon said on Capital Allocators that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Supported

Gordon: HCA IPOed at ~$30 per share and reached the mid-to-high $200s

“They went public at around 30 dollars a share, And I think the stock is currently somewhere in the mid to high 200.”

Chris Gordon Aug 28, 2023 ▶ 40:02 Classic Deal: HCA – Chris Gordon, Bain Capital (EP.335)

Appearances (1)

Episode	Date	Speaking time
Classic Deal: HCA – Chris Gordon, Bain Capital (EP.335)	Aug 28, 2023	43m